Andrew Scharenberg, Umoja Biopharma CEO
January 14, 2025 11:44 AM EST
Financing
Cell/Gene Tx

Umo­ja’s $100M Se­ries C will ad­vance its bid for more con­ve­nient cell ther­a­pies

Ayisha Sharma

News Reporter

In the 10th megaround of 2025, Umo­ja Bio­phar­ma has banked $100 mil­lion in a Se­ries C fundraise with an eye to ad­vanc­ing its pipeline of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Health­care shake­up hits Wash­ing­ton, with cuts at CDC, NIH and oth­er agen­cies

Ex­clu­sive: Drug­mak­ers plan Trump meet­ing next week amid Wash­ing­ton health shake­ups

ARPA-H chief is out as Trump ad­min­is­tra­tion cuts health agen­cies

Ko­jin Ther­a­peu­tics shuts down, cit­ing lack of in­vestor in­ter­est and com­plex sci­ence

How Bain’s $3.3B deal for cen­turies-old Tan­abe Phar­ma came to fruition

sponsored

Re­duc­ing risk in drug de­vel­op­ment: The im­por­tance of val­i­dat­ed MRD test­ing in lym­phoid can­cers

A service from the Financial Times